TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12664518
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (32 children with one dose of Tramadol 2 mg/kg)
Study: 1108694
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 20-25 ml of normal saline
Study: 7406657
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate (single oral dose)
Study: 28343801
Drug: ONS (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS (Oral Nutritional Supplements)
Study: 21883811
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (1 g 12-h)
Study: 18635696
Drug: SL65.1498 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: SL65.1498 (three doses)
Study: 17244295
Drug: Directly hired
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly hired workers (treatment group)
Study: 9800063
Drug: Conventional daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional daily wear soft contact lenses
Study: 25223369
Drug: Remogliflozin etabonate
Normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remogliflozin etabonate (RE) 50, 100, 250, 500 or 1000 mg twice daily
Study: 17084549
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg twice daily) with concurrent cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) and pelvic radiation therapy
Study: 9876503
Drug: Phenylbutazone tablets
Normalized name: Phenylbutazone Tablets
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylbutazone tablets
Study: 8011009
Drug: Multiple-unit formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-unit formulation (Diclo-Puren 50)
Study: 8011009
Drug: Single-unit formulation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-unit formulation (reference)
Study: 2575369
Drug: Cicletanine 50
Normalized name: cicletanine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 50 mg/day and Cicletanine 100 mg/day
Study: 1190365
Drug: Metronidazole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2.5 g during 5 days to 7.5 g in 10 days for children; 5 g in 5 days or 12.5 g in 10 days for adults)
Study: 25974235
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell therapy
Study: 29888663
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment during pregnancy
Study: 23774238
Drug: Sivelestat (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivelestat (0.2 mg/kg/hour continuous intravenous infusion)
Study: 16894407
Drug: Tramadol Contramid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol Contramid once-daily 200 mg tablets
Study: 16894407
Drug: Zytram 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zytram 200 mg tablets
Study: 12509627
Drug: Doloteffin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doloteffin (60 mg of harpagoside daily for 6 weeks)
Study: 12509627
Drug: Rofecoxib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5 mg/day for 6 weeks)
Study: 8706482
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg administered intravenously)
Study: 8706482
Drug: Placebo (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (equivalent administered intravenously)
Study: 1714011
Drug: ISDN +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISDN + NAC (600 mg q.i.d.)
Study: 6178382
Drug: Clorgyline, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorgyline, 5 to 10 mg every or every other day
Study: 10967698
Drug: Prazosin (sustained-release)
Normalized name: prazosin Extended Release Oral Tablet
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prazosin (sustained-release) 2.5 mg
Study: 8790198
Drug: 111In‐CYT‐103 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: 111In‐CYT‐103 (150 MBq; 1 mg)
Study: 8218966
Drug: Intramuscular tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular tenoxicam (20 mg)
Study: 8218966
Drug: Oral tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenoxicam (20 mg)
Study: 28628251
Drug: Single-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug regimens (Vemurafenib, Dabrafenib, Nivolumab)
Study: 28628251
Drug: Double-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug regimens (Dabrafenib + Trametinib, Nivolumab + Ipilimumab, Vemurafenib + Cobimetinib)
Study: 28628251
Drug: Single-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug regimens (Vemurafenib, Dabrafenib)
Study: 28628251
Drug: Double-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug regimens (Dabrafenib + Trametinib, Vemurafenib + Cobimetinib)
Study: 27368882
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy and breast surgery
Study: 24673050
Drug: Acupoint catgut
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint catgut implantation combined with artificial periodic therapy
Study: 24673050
Drug: Artificial periodic
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial periodic therapy with oral administration of medroxyprogesterone acetate tablets
Study: 20973708
Drug: Ritalin(®) LA
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritalin(®) LA 20 mg
Study: 15582637
Drug: Reminiscence intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reminiscence intervention (weekly for 4 months)
Study: 12397268
Drug: Carbohydrate-electrolyte rehydration
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte rehydration solution
Study: 8978228
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment need
Study: 8978228
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by prison health care services
Study: 1321859
Drug: Oka strain
Normalized name: Live attenuated Oka strain varicella vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka strain live attenuated varicella-zoster virus (VZV) vaccine, administered subcutaneously at doses varying from 1100 to 12,000 pfu, with one cohort receiving 3000 pfu and a 3000 pfu booster 3 months later.
Study: 1321859
Drug: Oka strain
Normalized name: Live attenuated Oka strain varicella vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka strain live attenuated varicella-zoster virus (VZV) vaccine
Study: 24118368
Drug: One-piece titanium
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece titanium implants
Study: 24118368
Drug: One-piece zirconia
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece zirconia implants
Study: 12075219
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.4 mg/mL applied for 4 minutes
Study: 6389378
Drug: Oral bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bumetanide
Study: 6389378
Drug: Intravenous bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bumetanide
Study: 31349792
Drug: 14-day ECG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day ECG monitoring patch (Zio® Patch, iRhythm Technologies)
Study: 28525614
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lidocaine (group RL40)
Study: 28525614
Drug: 1.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg/kg lidocaine (group LL1.2)
Study: 27128611
Drug: Ruxolitinib 25
Normalized name: ruxolitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 25 mg
Study: 27128611
Drug: Ruxolitinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 200 mg
Study: 16386524
Drug: Plasmapheresis (PP)
Normalized name: propoxyphene hydrochloride Oral Capsule [PP-Cap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmapheresis (PP) and intravenous immunoglobulin (IVIG)
Study: 337982
Drug: Testosterone cypionate,
Normalized name: testosterone cypionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone cypionate, 200 mg, intramuscularly weekly
Study: 29096835
Drug: Lipoprotein apheresis
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein apheresis (LA) treatment, weekly for 2 years
Study: 29096835
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated lipid lowering therapy (control group)
Study: 21498149
Drug: Emtricitabine (FTC)
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine (FTC) dosed once daily
Study: 21498149
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (3TC) dosed twice daily
Study: 19249153
Drug: Intermittent hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent hormonal therapy (IHT) with cyproterone acetate (CPA) 200mg for 2 weeks and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH) analogue plus 200mg of CPA daily during induction. Patients randomised to the intermittent arm ceased treatment.
Study: 19249153
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy with 200mg of CPA daily plus an LHRH analogue.
Study: 19249153
Drug: Intermittent hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent hormonal therapy (IHT)
Study: 9383182
Drug: Metoprolol (50-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50-250 mg/day)
Study: 9383182
Drug: Prazosin (3-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (3-20 mg/day)
Study: 3684175
Drug: aminoglutethimide 1000
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day
Study: 3684175
Drug: aminoglutethimide 250
Normalized name: aminoglutethimide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminoglutethimide 250 mg/day
Study: 27011002
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - once-daily (long-acting) for 4 weeks
Study: 27011002
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - highest dose
Study: 23959630
Drug: Strontium ranelate
Normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Strontium ranelate (SrRan) 2 g per day
Study: 23959630
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg per week
Study: 20226890
Drug: Ag85B-ESAT-6 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag85B-ESAT-6 vaccine with IC31 adjuvant
Study: 20226890
Drug: Ag85B-ESAT-6 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag85B-ESAT-6 vaccine without IC31 adjuvant
Study: 18344850
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy only (control)
Study: 12584366
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitors (among male subjects)
Study: 12584366
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitors (among female subjects)
Study: 10321419
Drug: Nabumetone 2000
Normalized name: Nabumetone
DrugBank: Nabumetone (DB00461)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nabumetone 2000 mg/d
Study: 10321419
Drug: Sulindac 400
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 400 mg/d
Study: 8723378
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release L-DOPA/carbidopa (100/25 mg)
Study: 6412390
Drug: Sodium heparin
Normalized name: Heparin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium heparin 5000 IU subcutaneously every 12 hours for 7 days
Study: 6412390
Drug: Semi-synthetic heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-synthetic heparin analogue (SSHA) 75 mg subcutaneously every 12 hours for 7 days
Study: 31957555
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement (2000 IU/day)
Study: 27910150
Drug: ONO-2952 20
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-2952 20 mg
Study: 27910150
Drug: ONO-2952 60
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-2952 60 mg
Study: 24901279
Drug: Placebo (inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inactivated laser treatment)
Study: 19243306
Drug: OXN PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN PR (60-80 mg/day)
Study: 19243306
Drug: OXY PR
Normalized name: Acarboxy prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXY PR alone (60-80 mg/day)
Study: 16331792
Drug: Synovial tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synovial tissue analysis in treatment strategies for rheumatoid arthritis
Study: 7778636
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (50 microgram tablets every 3 hours for a maximum of six doses)
Study: 7778636
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone (0.5 mg every 6 hours for a maximum of three doses)
Study: 7189333
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (2 mg/kg)
Study: 7189333
Drug: Lidocaine (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (21 mg/kg)
Study: 30528459
Drug: Intraneural injection
Normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraneural injection (1ml solution)
Study: 30528459
Drug: Perineural injection
Normalized name: ROPIVACAINE HYDROCHLORIDE 2 mg in 1 mL PERINEURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural injection (1ml solution)
Study: 28938956
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg followed by 90 mg twice daily
Study: 28938956
Drug: Clopidogrel 300
Normalized name: clopidogrel 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 300 mg followed by 75 mg daily
Study: 24117412
Drug: Reduced-fluence photodynamic
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin (25 J/cm²) followed by intravitreal bevacizumab 1.25 mg
Study: 24117412
Drug: Reduced-fluence photodynamic
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-fluence photodynamic therapy (RDPDT) with Verteporfin followed by intravitreal bevacizumab
Study: 21495900
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g E. officinalis powder per day
Study: 21495900
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g E. officinalis powder per day
Study: 21495900
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g E. officinalis powder per day
Study: 19535707
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine administered 30 min before 2-chloroprocaine anesthesia (n = 29)
Study: 19535707
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine administered after 2-chloroprocaine anesthesia (n = 30)
Study: 19535707
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine administered after lidocaine anesthesia (n = 28)
Study: 19535707
Drug: Supplemental morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental morphine equivalents administered in the first 48 h
Study: 17438515
Drug: Estrogen-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-containing oral contraceptives
Study: 17438515
Drug: Delayed hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed hormone therapy
Study: 15110204
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy administered to 134 patients (12%)
Study: 15110204
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy after propensity score analyses
Study: 11180010
Drug: Recombinant interleukin-10
Normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interleukin-10 administered subcutaneously over 6 weeks
Study: 8092234
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with short protocol using gonadotropin-releasing hormone agonist followed by human menopausal gonadotropin and human chorionic gonadotropin
Study: 24190112
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m² on days 1, 8, and 15, every 4 weeks)
Study: 24190112
Drug: Irinotecan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (150 mg/m² on days 1 and 15, every 4 weeks)
Study: 21944095
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment after initially waiting
Study: 12707158
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of lactated Ringer's solution 40 mL/kg
Study: 12707158
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion of lactated Ringer's solution 5 mL/kg
Study: 4016830
Drug: Mezlocillin (5-gm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (5-gm dose administered intravenously 30 minutes before surgery)
Study: 4016830
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered intravenously 30 minutes before surgery)
Study: 24239600
Drug: Hyangsa-Pyeongwi san
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyangsa-Pyeongwi san (HPS) 9.68g at once, three times daily for 4 weeks
Study: 21869730
Drug: enalapril FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril FA tablet (10 : 0.4 mg, low‐FA group)
Study: 21869730
Drug: enalapril FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril FA tablet (10 : 0.8 mg, high‐FA group)
Study: 21869730
Drug: enalapril only
Normalized name: Enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril only (10 mg, control group)
Study: 20569064
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy during tuberculosis therapy
Study: 20569064
Drug: Tuberculosis therapy
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberculosis therapy alone
Study: 18280582
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment for schizophrenia or schizophreniform disorders
Study: 14653235
Drug: Bougienage and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bougienage and omeprazole (20 mg/day for 12 months)
Study: 14653235
Drug: Bougienage and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bougienage and ranitidine (300 mg/day for 12 months)
Study: 1412119
Drug: Budesonide (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (1.6 mg inhaled per day for three weeks)
Study: 1412119
Drug: Prednisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (40 mg oral per day for eight days)
Study: 30988711
Drug: BIOF2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months)
Study: 30988711
Drug: BIOF2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIOF2 treatment (intra-articular BIOF2 application at 0, 1 and 2 months) excluding patients with class 2 obesity or malalignment
Study: 30988711
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical care (paracetamol/NSAIDs and general care provided by the family physician)
Study: 20195744
Drug: Ovarian function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian function suppression plus 5 years of tamoxifen with anthracycline-based chemotherapy
Study: 20195744
Drug: Ovarian function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian function suppression plus 5 years of tamoxifen without chemotherapy (endocrine therapy alone)